Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Or

(904) 244-0411 MyUFHealth Education Research Community

Treats Adults

Mehdi S Mirsaeidi, MD, MPH

Pulmonologist, Critical Care Medicine Physician

4.8 /5 148 ratings

Additional languages:: Persian

Request appointment online

Established patients New patients

Research at a glance

Top areas of exploration

Mycobacterium tuberculosis , 21 publications
Antitubercular Agents , 20 publications
COVID-19 , 18 publications
Tuberculosis, Pulmonary , 15 publications

Research activity

235 publications

8,469 citations

Why is this important?

Active clinical trials

A Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients with Pneumonia Due To COVID-19 or Respiratory Infections.

Investigator: Mehdi S Mirsaeidi
Status: Accepting Candidates
Ages: 18 Years - 100 Years
Sexes: All

A Study to Evaluate an Amikacin Liposome Inhalation Suspension Based Regimen in Adults with Newly Diagnosed NTM Lung Infection Caused by Mycobacterium avium Complex (MAC)

Investigator: Mehdi S Mirsaeidi
Status: Accepting Candidates
Ages: 18 Years - 100 Years
Sexes: All

A study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

Investigator: Mehdi S Mirsaeidi
Status: Accepting Candidates
Ages: 18 Years - 100 Years
Sexes: All

My publications

235 publications

2021

Long‐term exposure to indoor air pollution and risk of tuberculosis

Indoor Air

PubMed • Publisher's site

2021

Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying

Critical Care

PubMed • Publisher's site

2021

Mask-off policy in the shadow of emerging variants of SARS-COV-2

European Journal of Internal Medicine

PubMed • Publisher's site

2021

Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives.

Nanomedicine (London, England)

PubMed • Publisher's site

2021

Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response

Infection and Immunity

Publisher's site